What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design. Issue 4 (18th January 2021)

• Record Type: Journal Article
• Authors: Xiong, Muya; Su, Haixia; Zhao, Wenfeng; Xie, Hang; Shao, Qiang; Xu, Yechun
• Is Part Of: Medicinal research reviews. Volume 41:Issue 4(2021)
• Page Start: 1965
• Page End: 1998
• Publication Date: 2021-01-18
• Subjects: 3C‐like protease -- binding modes -- coronavirus -- inhibitors -- structure and function; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21783
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: The emergence of a variety of coronaviruses (CoVs) in the last decades has posed huge threats to human health. Especially, the ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to more than 70 million infections and over 1.6 million of deaths worldwide in the past few months. None of the efficacious antiviral agents against human CoVs have been approved yet. 3C‐like protease (3CL pro ) is an attractive target for antiviral intervention due to its essential role in processing polyproteins translated from viral RNA, and its conserved structural feature and substrate specificity among CoVs in spite of the sequence variation. This review focuses on all available crystal structures of 12 CoV 3CL pro s and their inhibitors, and intends to provide a comprehensive understanding of this protease from multiple aspects including its structural features, substrate specificity, inhibitor binding modes, and more importantly, to recapitulate the similarity and diversity among different CoV 3CL pro s and the structure–activity relationship of various types of inhibitors. Such an attempt could gain a deep insight into the inhibition mechanisms and drive future structure‐based drug discovery targeting 3CL pro s.